Palladyne has genuine defense and industrial revenue, a $24.6m Q2 backlog and promising partners. Yet no software product revenue had been reported through June 2026, while cash use and share issuance are material. At the 2026-10-21 $3.69 close, our $1.81 base case implies 50.9% downside; upside requires evidence that software collaboration becomes paid, scalable sales.
Methodology. FY2026 $25.5m is the midpoint of company guidance, not an extrapolated quarterly run rate. H1 revenue mix distributes the single 2.59x company multiple. June cash is reduced by one modeled quarter of cash use; no further ATM proceeds are assumed, and future shares are a risk rather than hidden in the base numerator. Forecast and peer inputs can change quickly. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Products operating EV | FY2026E $11.99m allocated from H1 mix × 2.59x / 49.34m shares | +0.629 |
| Development contracts operating EV | FY2026E $3.41m allocated from H1 mix × 2.59x / 49.34m shares | +0.179 |
| Engineering services operating EV | FY2026E $10.10m allocated from H1 mix × 2.59x / 49.34m shares | +0.530 |
| Reported liquid assets | 2026-06-30 $43.746m cash + securities / 49.34m shares | +0.887 |
| Estimated Q3 cash use | Modeled $6.8m burn: ($34m FY2026 guide midpoint − $20.401m H1 use) / 2 quarters; / 49.34m shares | -0.138 |
| Lease claims | 2026-06-30 current + long-term lease liabilities $10.557m / 49.34m shares | -0.214 |
| Warrant liability | 2026-06-30 mark-to-market liability $3.004m / 49.34m shares | -0.061 |
| Base case fair value | Sum of seven unrounded per-share components | 1.813 |
At $3.69 × 49.34m vendor shares, equity market value is about $182.1m. The price sits within the quoted 52-week range of $3.56–$10.00. June leases total $10.557m, warrant liabilities $3.004m, and liquid assets $43.746m.
| Metric ($m unless noted) | FY2024 | FY2025 | H1 2026 | FY2026 outlook |
|---|---|---|---|---|
| Revenue | 7.786 | 5.246 | 9.321 | 24–27 company guidance |
| Operating income / (loss) | (26.923) | (32.404) | (25.332) | Not guided |
| Net income / (loss) | (72.617) | +10.039* | (24.934) | Not guided |
| Operating cash flow | (22.627) | (27.637) | (20.401) | (32) to (36) cash-use guidance |
| Capital expenditure | (0.265) | (0.713) | (0.889) | Not guided |
| Free cash flow, OCF less capex | (22.892) | (28.350) | (21.290) | Not guided |
| Cash + marketable securities at period end | N/D | N/D | 43.746 | Not guided |
*FY2025 GAAP net income includes a $37.740m noncash warrant revaluation gain; it does not indicate profitable operations. H1 2026 free cash flow is operating cash flow less capital expenditure. FY2026 operating cash-use range is management guidance, not free cash flow guidance.
| Metric ($m unless noted) | Q3 2025† | Q4 2025 | Q1 2026† | Q2 2026 |
|---|---|---|---|---|
| Revenue | 0.860 | 1.661 | 3.538 | 5.783 |
| Gross margin | N/D | 15.6% | 30.1% | 29.1% |
| Operating loss | N/D | (9.314) | (11.919) | (13.413) |
| Net income / (loss) | N/D | (1.493) | (12.608) | (12.326) |
| Cash + securities at period end | N/D | N/D | N/D | 43.746 |
†Q3 2025 revenue is FY2025 less H1 and Q4; Q1 2026 revenue and net loss are H1 less Q2. Derived columns are identified; unreported metrics are N/D.
Q2 sales comprised $2.691m product, $1.179m product-development contracts and $1.913m engineering services. H1 mix was $4.382m, $1.246m and $3.693m, respectively. Product revenue reflects, among other things, manufacturing and BRAIN avionics businesses acquired in November 2025. The issuer reported no software product revenue through June. At the $32–36m FY2026 operating cash-use range ($8–9m per quarter), June liquid assets imply roughly 4.9–5.5 quarters of simple cash coverage before capital spending or financing; this is not a forecast of insolvency.
Business model — defense robotics and industrial automation
FANUC industrial channel September strategic collaboration can open robot deployments; economics and orders remain undisclosed. SwarmOS and unmanned systems NORDA and Orkid integrations broaden technical validation but are not recognized software-license sales. SwarmShot development October 7 joint development with Federal Ammunition and Mossberg is a product initiative, not a disclosed purchase order. BRAIN / defense work Funded backlog gives near-term revenue visibility if programs execute; October 6 Army competition finalist status is not an award.
Legal, regulatory and risk analysis
SWOT analysis
- +$21.2m funded Q2 backlog
- +Real defense and industrial engineering revenue
- +Low funded financial debt
- +Multiple strategic customer channels
- −No software product revenue through June
- −Deep operating losses and cash burn
- −29.1% Q2 gross margin
- −ATM share issuance
- →Conversion of FANUC cooperation to orders
- →SwarmOS adoption in unmanned aircraft
- →BRAIN avionics defense expansion
- →Scale benefit if acquired businesses integrate
- !Further equity dilution
- !Defense award delays and cancellation
- !Competition from larger incumbents
- !Software premium may compress
Summary by assessment area
- $1.81 base fair value versus $3.69 close; 50.9% modeled downside.
- 1.0x EV/revenue sensitivity changes value by about $0.52 per share.
- $43.746m June liquid assets against $32–36m FY2026 operating cash-use guidance.
- ATM issuance and warrants create dilution/accounting complexity.
- $21.2m funded backlog supports activity; delivery and collections matter.
- Paid FANUC/software orders would change the quality of revenue.
- Q2 gross margin was 29.1% and operating loss $13.413m.
- A software premium requires booked license revenue and lower cash burn.
Primary sources: SEC Q2 2026 Form 10-Q ; Q2 2026 earnings release and guidance ; FY2025 results ; FANUC announcement ; SwarmShot announcement . Market and peer data: PDYN close and 52-week range ; second price check ; September short interest ; PDYN share statistics ; analyst target snapshot ; RCAT , AVAV , KTOS , ONDS . Financial statements are issuer-reported; share count, short interest and peer multiples are vendor snapshots. Future catalyst dates and unreported cash are analytical estimates, not issuer guidance. Source review completed 2026-10-22. ⚠️ Not investment advice.